Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2009-04-02
2011-12-20
Gibbs, Terra Cotta (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S023100, C536S024300, C536S024330, C536S024500
Reexamination Certificate
active
08080532
ABSTRACT:
The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Huntingtin gene (HD gene), comprising an antisense strand having a nucleotide sequence which is less than 25 nucleotides in length and which is substantially complementary to at least a part of the HD gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the HD gene, or a mutant form thereof, using the pharmaceutical composition; and methods for inhibiting the expression of the huntingtin gene in a cell.
REFERENCES:
patent: 7320965 (2008-01-01), Sah et al.
patent: 7589189 (2009-09-01), Ichiro et al.
patent: 2003/0143732 (2003-07-01), Fosnaugh et al.
patent: 2004/0259247 (2004-12-01), Tuschl et al.
patent: 2005/0096284 (2005-05-01), McSwiggen
patent: 2007/0004664 (2007-01-01), McSwiggen et al.
patent: 2007/0031844 (2007-02-01), Khvorova et al.
patent: 2007/0105803 (2007-05-01), Manoharan et al.
patent: 2008/0039415 (2008-02-01), Stewart et al.
patent: WO 2004/058940 (2004-07-01), None
Harper, S.Q. et al., “RNA Interference Improves Motor and Neuropathological Abnormalities in a Huntington's Disease Mouse Model,” PNAS, Apr. 19, 2005, pp. 5820-5825, vol. 102, No. 16.
Rodriguez-Lebron, E. et al., “Intrastriatal rAAV-Mediated Delivery of Anti-huntingtin shRNAs Induces Partial Reversal of Disease Progression in R6/1 Huntington's Disease Transgenic Mice,” Molecular Therapy, Oct. 2005, pp. 618-633, vol. 12, No. 4.
Wang, Y.L. et al., “Clinico-pathological Rescue of a Model Mouse of Huntington's Disease by siRNA,” Neuroscience Research, Nov. 2005, Epub Aug. 10, 2005, pp. 241-249, vol. 53, No. 3.
Haque, N., et al., “Antisense Gene Therapy for Neurodegenerative Disease?” Experimental Neurology, 1997, pp. 139-146, vol. 144.
Park, C., et al., “Double-stranded siRNA targeted to theHuntingtingene does not induce DNA methylation,” Biochemical and Biophysical Research Communications, Oct. 8, 2004, pp. 275-280, vol. 323, No. 1.
Yuan, B., et al., siRNA Selection Server: an automated siRNA oligonucleotide prediction server, Nucleic Acids Research, 2004, pp. W130-W134, vol. 32.
Supplementary European Search Report for European Patent Application No. EP 06827135, Sep. 30, 2010, 10 Pages.
Examiner's First Report on Australia Patent Application No. 2006305886, Aug. 18, 2010, 3 pages.
Bass, B., “The short answer,” Nature, May 24, 2001, pp. 428-429, vol. 411.
Elbashir, S., et al., “Analysis of gene function in somatic mammalian cells using small interfering RNAs,” Methods, 2002, pp. 199-213, vol. 26.
Elbashir, S., et al., “Duplexes of 21-nucleotide RNAs mediate RNA interference in mammalian cell culture,” Nature, May 24, 2001, p. 494-498, vol. 411.
Elbashir, S., et al., “RNA Interference is Mediated By 21- and 22 Nucleotide RNAs,” Genes & Development, 2001, pp. 188-200, vol. 15.
Fire, A., “RNA-triggered Gene Silencing,” Trends in Genetics, Sep. 1999, pp. 358-363, vol. 15, No. 9.
Fire, A., et al., “Potent and Specific Genetic Interference By Double Stranded RNA in Caenorhabditis elegans,” Nature, Feb. 19, 1998, pp. 806-811, vol. 391.
Tuschl, T., “Functional genomics: RNA sets the standard,” Nature, Jan. 16, 2003, vol. 421, No. 6920, pp. 220-221.
Tuschl T., “RNA Interference and Small Interfering RNAs” Chembiochem, 2001, pp. 239-245, vol. 2.
Tuschl, T., et al., “Small Interfering RNAs: A Revolutionary Tool for the Analysis of Gene Function and Gene Therapy,” Molecular Interventions, 2002, pp. 158-167, vol. 2, No. 3.
Tuschl, T., “Mammalian RNA Interference,” RNAi, A Guide to Gene Silencing, Chapter 13, G.J. Hannon (ed,), 2003, pp. 265-295.
Tuschl, T., et al., “Targeted mRNA Degradation By Double-Stranded RNA In Vitro,” Genes & Development, 1999, pp. 3191-3197, vol. 13.
Tuschl, T., “Expanding small RNA interference,” Nature Biotechnology, May 2002, pp. 446-448, vol. 20.
Vickers, T., et al., “Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents,” The Journal of Biological Chemistry, Feb. 28, 2003, pp. 7108-7118, vol. 278, No. 9.
European Search Report for European Patent Application No. EP 11000550, Apr. 26, 2011, 6 Pages.
Bramlage Birgit
Bumcrot David
Hadwiger Philipp
Roehl Ingo
Sah Dinah Wen-Yee
Alnylam Pharmaceuticals, Inc.
Fenwick & West LLP
Gibbs Terra Cotta
LandOfFree
Compositions and methods for inhibiting expression of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for inhibiting expression of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for inhibiting expression of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4301785